vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and Goosehead Insurance, Inc. (GSHD). Click either name above to swap in a different company.
AVANOS MEDICAL, INC. is the larger business by last-quarter revenue ($180.9M vs $93.1M, roughly 1.9× Goosehead Insurance, Inc.). Goosehead Insurance, Inc. runs the higher net margin — 8.6% vs -0.7%, a 9.4% gap on every dollar of revenue. On growth, Goosehead Insurance, Inc. posted the faster year-over-year revenue change (23.1% vs 0.7%). Over the past eight quarters, Goosehead Insurance, Inc.'s revenue compounded faster (9.2% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Goosehead Insurance is a U.S.-based personal lines insurance agency that offers a wide range of coverage products including auto, home, renters, flood, and specialty insurance. It partners with hundreds of insurance carriers to provide clients with tailored, cost-effective coverage options, operating via corporate locations and a national franchise network for independent agents.
AVNS vs GSHD — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $93.1M |
| Net Profit | $-1.3M | $8.0M |
| Gross Margin | 47.5% | — |
| Operating Margin | 1.4% | 16.1% |
| Net Margin | -0.7% | 8.6% |
| Revenue YoY | 0.7% | 23.1% |
| Net Profit YoY | 99.7% | 204.0% |
| EPS (diluted) | $-0.02 | $0.19 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $93.1M | ||
| Q4 25 | $180.9M | $105.3M | ||
| Q3 25 | $177.8M | $90.4M | ||
| Q2 25 | $175.0M | $94.0M | ||
| Q1 25 | $167.5M | $75.6M | ||
| Q4 24 | $179.6M | $93.9M | ||
| Q3 24 | $170.4M | $78.0M | ||
| Q2 24 | $171.7M | $78.1M |
| Q1 26 | — | $8.0M | ||
| Q4 25 | $-1.3M | $12.4M | ||
| Q3 25 | $-1.4M | $7.9M | ||
| Q2 25 | $-76.8M | $5.2M | ||
| Q1 25 | $6.6M | $2.3M | ||
| Q4 24 | $-397.3M | $14.9M | ||
| Q3 24 | $4.3M | $7.6M | ||
| Q2 24 | $1.8M | $6.2M |
| Q1 26 | — | — | ||
| Q4 25 | 47.5% | — | ||
| Q3 25 | 48.4% | — | ||
| Q2 25 | 52.6% | — | ||
| Q1 25 | 53.6% | — | ||
| Q4 24 | 54.6% | — | ||
| Q3 24 | 54.5% | — | ||
| Q2 24 | 55.7% | — |
| Q1 26 | — | 16.1% | ||
| Q4 25 | 1.4% | 29.4% | ||
| Q3 25 | 0.1% | 23.5% | ||
| Q2 25 | -42.6% | 16.7% | ||
| Q1 25 | 6.1% | 8.8% | ||
| Q4 24 | -233.0% | 29.7% | ||
| Q3 24 | 7.0% | 21.1% | ||
| Q2 24 | 3.7% | 19.7% |
| Q1 26 | — | 8.6% | ||
| Q4 25 | -0.7% | 11.8% | ||
| Q3 25 | -0.8% | 8.7% | ||
| Q2 25 | -43.9% | 5.5% | ||
| Q1 25 | 3.9% | 3.1% | ||
| Q4 24 | -221.2% | 15.8% | ||
| Q3 24 | 2.5% | 9.7% | ||
| Q2 24 | 1.0% | 7.9% |
| Q1 26 | — | $0.19 | ||
| Q4 25 | $-0.02 | $0.48 | ||
| Q3 25 | $-0.03 | $0.29 | ||
| Q2 25 | $-1.66 | $0.18 | ||
| Q1 25 | $0.14 | $0.09 | ||
| Q4 24 | $-8.64 | $0.58 | ||
| Q3 24 | $0.09 | $0.29 | ||
| Q2 24 | $0.04 | $0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $25.7M |
| Total DebtLower is stronger | $90.3M | — |
| Stockholders' EquityBook value | $778.2M | $-121.3M |
| Total Assets | $1.1B | $392.8M |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $25.7M | ||
| Q4 25 | $89.8M | $34.4M | ||
| Q3 25 | $70.5M | $51.6M | ||
| Q2 25 | $90.3M | $92.4M | ||
| Q1 25 | $97.0M | $70.2M | ||
| Q4 24 | $107.7M | $54.3M | ||
| Q3 24 | $89.0M | $47.5M | ||
| Q2 24 | $92.2M | $23.6M |
| Q1 26 | — | — | ||
| Q4 25 | $90.3M | $289.5M | ||
| Q3 25 | $93.4M | $290.0M | ||
| Q2 25 | $95.7M | $289.8M | ||
| Q1 25 | $98.0M | $290.3M | ||
| Q4 24 | $125.3M | $82.3M | ||
| Q3 24 | $152.6M | $84.6M | ||
| Q2 24 | $164.9M | $87.0M |
| Q1 26 | — | $-121.3M | ||
| Q4 25 | $778.2M | $-95.5M | ||
| Q3 25 | $778.0M | $-105.0M | ||
| Q2 25 | $776.3M | $-78.6M | ||
| Q1 25 | $839.4M | $-88.5M | ||
| Q4 24 | $828.5M | $43.9M | ||
| Q3 24 | $1.2B | $58.3M | ||
| Q2 24 | $1.2B | $39.8M |
| Q1 26 | — | $392.8M | ||
| Q4 25 | $1.1B | $414.9M | ||
| Q3 25 | $1.1B | $403.6M | ||
| Q2 25 | $1.0B | $436.6M | ||
| Q1 25 | $1.1B | $412.6M | ||
| Q4 24 | $1.2B | $397.7M | ||
| Q3 24 | $1.7B | $358.1M | ||
| Q2 24 | $1.7B | $338.2M |
| Q1 26 | — | — | ||
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | 1.87× | ||
| Q3 24 | 0.12× | 1.45× | ||
| Q2 24 | 0.13× | 2.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | — |
| Free Cash FlowOCF − Capex | $21.3M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 3.8% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $28.2M | $91.8M | ||
| Q3 25 | $14.0M | $24.2M | ||
| Q2 25 | $6.8M | $28.9M | ||
| Q1 25 | $25.7M | $15.5M | ||
| Q4 24 | $57.9M | $71.5M | ||
| Q3 24 | $23.0M | $28.1M | ||
| Q2 24 | $27.8M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | $21.3M | $86.1M | ||
| Q3 25 | $7.0M | $23.7M | ||
| Q2 25 | $-4.2M | $27.2M | ||
| Q1 25 | $19.0M | $14.9M | ||
| Q4 24 | $53.1M | $70.6M | ||
| Q3 24 | $20.0M | $28.0M | ||
| Q2 24 | $21.9M | $18.6M |
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | 81.8% | ||
| Q3 25 | 3.9% | 26.2% | ||
| Q2 25 | -2.4% | 28.9% | ||
| Q1 25 | 11.3% | 19.7% | ||
| Q4 24 | 29.6% | 75.1% | ||
| Q3 24 | 11.7% | 35.9% | ||
| Q2 24 | 12.8% | 23.9% |
| Q1 26 | — | — | ||
| Q4 25 | 3.8% | 5.4% | ||
| Q3 25 | 3.9% | 0.5% | ||
| Q2 25 | 6.3% | 1.8% | ||
| Q1 25 | 4.0% | 0.8% | ||
| Q4 24 | 2.7% | 1.0% | ||
| Q3 24 | 1.8% | 0.1% | ||
| Q2 24 | 3.4% | 0.3% |
| Q1 26 | — | — | ||
| Q4 25 | — | 7.38× | ||
| Q3 25 | — | 3.06× | ||
| Q2 25 | — | 5.61× | ||
| Q1 25 | 3.89× | 6.61× | ||
| Q4 24 | — | 4.82× | ||
| Q3 24 | 5.35× | 3.72× | ||
| Q2 24 | 15.44× | 3.05× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
GSHD
| Renewal Royalty Fees (2) | $43.6M | 47% |
| Renewal Commissions (1) | $18.2M | 20% |
| Contingent Commissions (1) | $10.7M | 11% |
| New Business Royalty Fees (2) | $7.9M | 8% |
| New Business Commissions (1) | $7.5M | 8% |
| Other | $3.7M | 4% |
| Initial Franchise Fees (2) | $1.6M | 2% |
